
Shares of Moderna MRNA.O fall 8% to ~$39 in extended trading
MRNA says U.S. Food and Drug Administration will not review approval application for its influenza vaccine
Says refusal to review submission is inconsistent with feedback at pre-phase 3 and pre-submission consultations
Says requested a meeting with the Center for Biologics Evaluation and Research to understand basis for refusal
In 2025, MRNA fell over 29%